netbook
desktop
mobile
tablet-landscape
tablet
phone-landscape
phone
Research to Prevent Blindness

Alternative Treatment for Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy (PDR), a complication of diabetes that damages blood vessels in the light-sensitive retina in the back of the eye. Lucentis is used to treat wet macular degeneration as well as diabetic macula edema. The study found the treatment no less effective than the laser therapy which currently is the standard treatment for PDR.

Read the press release.

Read the study.

In a RPB-supported commentary, Timothy W. Olsen, MD, notes that "this important study [...] represents a major step forward for patients with PDR by providing the ophthalmologists who manage their retinal disease with new options." But he adds a cautionary note. 

Read the commentary.

 

Related News: Diabetic Retinopathy, Top Story

test tubes

The Time is Now to Protect the National Eye Institute

The existence of the National Eye Institute, the most important source of funding for vision research in the U.S., is being threatened.

Read More

 
eye brain connection

RPB Grantees Contribute to Eye Transplantation Effort

The ARPA-H THEA project takes on an exciting challenge.

Read More

 
microscope

Faulty Vision for US Eye Research

An important message from an RPB Trustee

Read More

 
Giving Tuesday logo

Giving the Gift of Sight

#GivingTuesday kicks off with a donation match

Read More

 
eye photo

New Grants for Big Data Research to Improve Vision Care

Read More

 
RPB Logo

Research to Prevent Blindness Opens Applications for Vision Research Grants

The awards offered cover a wide variety of topics in vision science, including glaucoma, age-related macular degeneration, retinal diseases, and many more.

Read More

 

Subscribe

Get our email updates filled with the latest news from our researchers about preventing vision loss, treating eye disease and even restoring sight. Unsubscribe at any time. Under our privacy policy, we'll never share your contact information with a third party.